首页分子通1-(5-tert-butyl-2-methyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-3-{[(2-hydroxyethyl)methylamino]methy}piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}urea hydrogen chloride salt
1-(5-tert-butyl-2-methyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-3-{[(2-hydroxyethyl)methylamino]methy}piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}urea hydrogen chloride salt
1-(5-tert-butyl-2-methyl-2H-pyrazol-3-yl)-3-{(1S,4R)-4-[3-((S)-3-{[(2-hydroxyethyl)methylamino]methy}piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}urea hydrogen chloride salt
[EN] KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASES
申请人:CHIESI FARMA SPA
公开号:WO2014195400A1
公开(公告)日:2014-12-11
This invention relates to compounds and compositions that are p38 MAPK inhibitors, useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.